ENTX — Entera Bio Balance Sheet
0.000.00%
- $107.19m
- $98.53m
- $0.18m
Annual balance sheet for Entera Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.59 | 24.9 | 12.3 | 11 | 8.66 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.255 | 0.183 | 0.246 | 0 | 0.126 |
Total Other Current Assets | |||||
Total Current Assets | 9.11 | 25.3 | 12.8 | 11.3 | 8.97 |
Net Property, Plant And Equipment | 0.566 | 0.395 | 0.229 | 0.488 | 0.332 |
Other Long Term Assets | |||||
Total Assets | 9.72 | 26 | 13.1 | 11.8 | 9.39 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.84 | 3.16 | 1.34 | 1.09 | 1.18 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.21 | 3.42 | 1.37 | 1.38 | 1.31 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 7.51 | 22.6 | 11.8 | 10.4 | 8.08 |
Total Liabilities & Shareholders' Equity | 9.72 | 26 | 13.1 | 11.8 | 9.39 |
Total Common Shares Outstanding |